Kathryn Dane

TL;DR: The evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in decisions about the use of anticoagulation for thromboprophylaxis for patients with COVID-19-related critical illness and acute illness who do not have confirmed or suspected venous thromboembolism (VTE) as mentioned in this paper.

TL;DR: Stoke is common after recovery from TTP and is associated with reduced ADAMTS13 activity during remission, according to this retrospective-prospective cohort study.

TL;DR: In the coming years, it is optimistic that novel therapies and international collaborative efforts will usher in even more effective, evidence-based approaches to address refractory acute TTP and relapse prevention.

TL;DR: In 2019, the American Society of Hematology (ASH) developed guidelines to support patients, clinicians, and other health care professionals in making decisions about the use of anticoagulation for thromboprophylaxis in patients with COVID-19-related critical illness who do not have confirmed or suspected venous thromboembolism (VTE) as discussed by the authors.

TL;DR: This conditional recommendation was based on very low certainty in the evidence, underscoring the need for additional, high-quality, randomized controlled trials comparing different intensities of anticoagulation in patients with COVID-19-related acute illness.